News | Robotic Systems | May 16, 2017

Large Multicenter Study Shows High Success Rate for Robotic PCI Procedures

Study presented at SCAI marks first time robotic system shown to be successful with complex lesions at multiple sites

Large Multicenter Study Shows High Success Rate for Robotic PCI Procedures, SCAI, Corindus CorPath 200

May 16, 2017 — The largest real-world study of robotic percutaneous coronary intervention (PCI) demonstrated clinical and technical success for patients across multiple sites using multiple operators. Results from the PRECISION trial (Efficacy and Safety Outcomes of Radial- vs Femoral-Access Robotic Percutaneous Coronary Intervention: Final Results of the Multicenter PRECISION Registry) were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions, May 10-13 in New Orleans.

While previous studies have evaluated PCI procedures performed manually versus robotically and shown similar results, limited data exist when comparing radial (wrist access) and femoral (groin area access) robotic PCI procedures.

“This is the first time we are demonstrating that the robotic system can be used, with either a radial or femoral approach, with high clinical and technical success in multiple sites with multiple operators,” said Ehtisham Mahmud, M.D., FACC, FSCAI, the study’s lead author and division chief, cardiovascular medicine and director, Sulpizio Cardiovascular Center at the University of California, San Diego School of Medicine.

The multicenter PRECISION registry, which included 16 U.S. sites, collected clinical and procedural data of Corindus Vascular Robotics’ CorPath 200 System, the first U.S. Food and Drug Administration (FDA)-approved generation robotic technology to remotely control coronary guidewires and stents for PCI patients. Technical success was defined as procedural success (residual stenosis <30 percent, TIMI 3 flow) with robotic PCI without manual assistance and absence of in-hospital major adverse cardiovascular events (MACE). Clinical success was determined by procedural success without in-hospital MACE.

The study comprised of 754 robotic PCI procedures with 949 lesions (63.4 percent type B2/C) treated with robotic PCI using transradial access (TRA) in 452 procedures and transfemoral access (TFA) in 298 procedures. Results demonstrated high technical (88.6 percent TRA vs 82.4 percent TFA; p=0.017) and clinical success rates (98.9 percent TRA vs 94.9 percent TFA; p=0.0012). Eighteen serious adverse events, unrelated to the CorPath 200 System, occurred (1.99 percent TRA vs 3.02 percent TFA, p=0.47); six were determined to be major adverse cardiac events, all of which occurred with transfemoral access.

“In unadjusted analysis, it appears that there may be slightly better outcomes with the radial approach,” noted Mahmud. “However, there were significant baseline demographic and angiographic differences between the two groups, with radial access patients being less complicated. After conducting a propensity score matched analysis, no differences were observed between the two approaches. Although, there was a slightly superior clinical success with radial access, it was likely the result of patient selection.”

Most importantly, according to Mahmud, the data presented show that using robotic technology to perform PCI in clinical practice via the radial or femoral approach is feasible, safe and effective. A future iteration of the technology (CorPath GRX) has recently been FDA-approved, enabling robotic guide catheter control, and should reduce the rates of manual assistance or conversion.

For more information: www.scaiscientificsessions.org

Related Content

News | Heart Failure| May 22, 2017
Serelaxin failed to meet the primary endpoints of the phase 3 RELAX-AHF-2 trial, according to late-breaking results...
Consumers Warned About Accuracy of Heart Rate Apps in New Study
News | Mobile Devices| May 22, 2017
May 22, 2017 — Consumers are being warned about the accuracy of heart rate apps after a study found huge variability
Abbott recalls its NC Balloon catheters
News | Balloon Catheter| May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Spectranetics Bridge Occlusion Balloon in the SVC

An illustration of how the Bridge balloon can seal the SVC after an accidental tear from lead extration.

Feature | EP Lab| May 17, 2017 | Dave Fornell
May 17, 2017 — A new intravenous occlusion balloon designed to seal any accidental tears in the superior vena cava (S
Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System
News | Peripheral Arterial Disease (PAD)| May 17, 2017
Contego Medical LLC announced recently that it has received CE Marking of its Vanguard IEP Peripheral Balloon...
Early Treatment for NSTEMI Patients Shows Greater Rate of Survival
News | Cath Lab| May 16, 2017
An analysis of non ST-elevation myocardial infarction (NSTEMI) patients who undergo coronary revascularization within...
micra leadless pacemaker
Feature | Pacemakers| May 16, 2017
May 16, 2017 - The preliminary results for the Medtronic Micra Transcatheter Pacing System (TPS) Post-Approval Regist
Overlay Init